AMSBIO announces the first commercially available gamma H2AX Pharmacodynamic assay kit for the study of double strand DNA breaks through the detection of gamma H2AX - a phosphorylated histone historically proven as a highly specific and sensitive molecular marker for double strand DNA damage detection.

This new assay has been developed for anti-cancer drug screening, basic research and upcoming clinical trials providing one of many needed tools to support hypothesis-driven drug design strategies. 

Documented variability in DNA double-strand break repair among different segments of the human population may contribute to patient specific therapeutic toxicities, enabling a more personalized approach to treatment. A quantitative determination of gamma-H2AX levels in response to treatment would help to establish patient specific dose regimens minimizing the toxicity, while maximizing the efficacy of therapy.  

Until now, induction of gamma-H2AX has been determined by either Western Blots or scoring foci with Immunofluorescence. While Western Blots provide information regarding the gamma-H2AX protein, they are difficult to quantitate and provide mostly qualitative data. Although image analysis software enables foci quantification, actual gamma-H2AX levels cannot be determined by these techniques, as there is no direct relationship between foci and gamma-H2AX levels after damage.

AMSBIO's new 96-well non-radioactive ELISA assay documents differences in gamma H2AX levels in peripheral blood mononuclear cells, cultured cells, and tissue biopsies and is available as a complete reagent kit with chemiluminescent detection. 

Alexei Degretev from Tufts University (Medford, USA), one of the initial beta testers of the product, commented "This new gamma H2AX pharmacodynamic assay is a very useful tool for providing precise quantitation of gamma H2AX formation. The assay is easy to perform, fast, and displays good linear range and excellent reproducibility between replicate samples".

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.

more about ams biotechnology

more news from ams biotechnology